Research programme: Anti-bacterials - KBP Biosciences

Drug Profile

Research programme: Anti-bacterials - KBP Biosciences

Alternative Names: KBP 7909; KBP-7963

Latest Information Update: 09 Sep 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KBP Biosciences
  • Class
  • Mechanism of Action Bacterial outer membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections; Gram-positive infections; Pseudomonal infections

Most Recent Events

  • 03 Sep 2014 Preclinical trials in Gram-negative infections in China (PO)
  • 03 Sep 2014 Preclinical trials in Pseudomonal infections in China (unspecified route)
  • 03 Sep 2014 Preclinical trials in Gram-positive infections in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top